We recently showed that telomeric repeat-binding factor 2 (TRF2) regulates gene expression to promote angiogenesis. We found that TRF2 is highly expressed in tumor vessels and transcriptionally activates platelet-derived growth factor receptor β to promote endothelial cell angiogenic properties independently of its function in telomere protection. This work identifies TRF2 as a promising dual target for cancer therapy.
Keywords: Wilms’ tumor suppressor WT1; telomeres; telomeric repeat-binding factor 2 (TRF2); transcriptional regulation; tumor angiogenesis.